Lion Biotechnologies (NASDAQ:LBIO) : Traders are bullish on Lion Biotechnologies (NASDAQ:LBIO) as it has outperformed the S&P 500 by a wide margin of 11.73% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.07%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2.37% in the last 1 week, and is up 13.54% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have dropped -4.64% from its 1 Year high price. On Jul 17, 2015, the shares registered one year high at $10.29 and the one year low was seen on Mar 29, 2016. The 50-Day Moving Average price is $7.41 and the 200 Day Moving Average price is recorded at $6.07.
The stock has recorded a 20-day Moving Average of 9.24% and the 50-Day Moving Average is 29.4%.
Lion Biotechnologies (NASDAQ:LBIO): stock turned positive on Friday. Though the stock opened at $8.38, the bulls momentum made the stock top out at $8.75 level for the day. The stock recorded a low of $8.21 and closed the trading day at $8.64, in the green by 3.23%. The total traded volume for the day was 611,827. The stock had closed at $8.37 in the previous days trading.
In an insider trading activity, Hillsberg Sanford, director of Lion Biotechnologies, Inc., unloaded 32,500 shares at an average price of $6.99 on September 4, 2015. The total amount of the transaction was worth $227,175, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Lion Biotechnologies, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing adoptive cell therapy (ACT) using autologous tumor infiltrating lymphocytes (TILs) for the treatment of metastatic melanoma and other solid cancers. The Companys program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients tumors, for the treatment of metastatic melanoma. Once the TILs have been multiplied to a sufficient number ex vivo and after the patient has completed the non-myeloablative chemotherapeutic regimen the TILs are infused into the patient along with a high dose of interleukin2 (IL2) a protein that stimulates the immune system.